<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221763</url>
  </required_header>
  <id_info>
    <org_study_id>18HH4801</org_study_id>
    <secondary_id>FS/19/4/34013</secondary_id>
    <nct_id>NCT04221763</nct_id>
  </id_info>
  <brief_title>Mechanisms and Innovations in Cardiac Resynchronisation Therapy</brief_title>
  <acronym>MIC</acronym>
  <official_title>Evaluation of Mechanisms and Innovations in Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effectiveness of multiple modalities of cardiac
      resynchronisation therapy using high precision acute electrical and haemodynamic
      measurements.These modalities include biventricular pacing and conduction system pacing
      utilising His bundle and left bundle pacing. Conduction system pacing is a more physiological
      form of pacing. We hypothesise that this will produce more effective cardiac
      resynchronisation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single centre acute electrical/haemodynamic and observational study of a subgroup
      of patients with heart failure. A total of 60 will be recruited. The acute study involves
      within patient comparison of biventricular and conduction system pacing using detailed
      electrical mapping and high precision haemodynamic measurement protocol.

      Participants will have permanent conduction system pacing if;

        -  Baseline left bundle branch block and QRS &gt; 140ms or QRS &gt;150ms and any QRS morphology
           AND

        -  Conduction system pacing is successful at reducing QRS duration by 20ms or more with
           satisfactory pacing parameters.

      Participants who receive permanent conduction system pacing will have follow up at 6 weeks, 3
      months, 6 months and 12 months. Non-invasive markers including mechanical activation pattern
      (echocardiography and cardiac MRI) and electrical activation pattern (ultra-high frequency
      electrocardiography) will be used to identify the characteristics of patients who benefit
      from conduction system pacing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>60 patients with heart failure, severe left ventricular systolic dysfunction and cardiac conduction abnormality (QRS &gt; 120ms) will be recruited and undergo an attempt at His bundle, left bundle pacing and biventricular pacing. Patients will have acute haemodynamic and electrical measurements.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute change is systolic blood pressure</measure>
    <time_frame>20 minutes</time_frame>
    <description>Mean change in systolic blood pressure (mmHg) from atrial pacing to AV sequential CRT pacing (HBP, LBP, epiBVP and combined HPB with epiLVP) at optimal AV delay measured in mmHg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute electrical measurements</measure>
    <time_frame>20 minutes</time_frame>
    <description>Mean change in left ventricular activation time (Milliseconds) (measured using ECGI) during AV sequential CRT pacing (HBP, LBP, epiBVP and combined HPB with epiLVP) at optimal AV delay measured in Milliseconds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conduction system battery longevity</measure>
    <time_frame>6 weeks, 3 months, 6 months, 12 months.</time_frame>
    <description>The measurements include battery longevity measured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conduction system lead threshold</measure>
    <time_frame>6 weeks, 3 months, 6 months, 12 months.</time_frame>
    <description>The measurements include lead threshold to achieved QRS narrowing measured in Volts at 0.5ms and 1ms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>Heart failure symptoms of patients with permanent conduction system leads will be assessed at follow up at 3 month, 6 months and 12 months. The symptoms will be assessed using the Minnesota living with heart failure questionnaire score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Patients with permanent conduction system leads will undergo a repeat echocardiography and measure their left ventricular ejection fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise testing</measure>
    <time_frame>6 months</time_frame>
    <description>Patients with permanent conduction system leads will undergo symptom assessment with a repeat cardio-pulmonary exercise test to measure MVO2 in litres/minute.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <condition>Left Bundle-Branch Block</condition>
  <condition>Right Bundle-Branch Block</condition>
  <condition>Non-Specific Intraventricular Conduction Defect</condition>
  <arm_group>
    <arm_group_label>Heart failure and abnormal cardiac conduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have an attempt at His-bundle pacing, left bundle pacing and biventricular pacing. Pacing at the His bundle and the left bundle will be attempted using a Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Biventricular pacing will utilise a left ventricular lead placed in the coronary sinus using any of the 5 manufactures of CS leads Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical or in participants receiving permanent conduction system pacing left ventricular pacing will be achieved using a Cordis ATW™ wire placed in the coronary sinus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>His-bundle pacing.</intervention_name>
    <description>Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.</description>
    <arm_group_label>Heart failure and abnormal cardiac conduction</arm_group_label>
    <other_name>Left bundle pacing</other_name>
    <other_name>Biventricular pacing</other_name>
    <other_name>Combined His-bundle and left ventricular epicardial pacing (HOT-CRT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred for conventional CRT

          -  Severe heart failure (LVEF, a measure of heart pumping, &lt; 35% - severe)

          -  Prolonged QRS duration (&gt;120ms)

          -  Adults willing to take part (age &gt; 18 years)

          -  Able to give consent

        Exclusion Criteria:

          -  Unable to give consent

          -  Children (age &lt; 18 years)

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary Whinnett, BM BS B</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadine Ali, BMBcH</last_name>
    <phone>07747462436</phone>
    <email>n.ali@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zachary Whinnett, BM BS B</last_name>
    <phone>02083834967</phone>
    <email>z.whinnett@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hammersmith Hospital Imperial College NHS trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Ali, BM BcH</last_name>
      <phone>07747462436</phone>
      <email>n.ali@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ahran Arnold, MBBS</last_name>
    </contact_backup>
    <investigator>
      <last_name>Nadine Ali, BM BcH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahran Arnold, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec;34(46):3547-56. doi: 10.1093/eurheartj/eht290. Epub 2013 Jul 29. Review.</citation>
    <PMID>23900696</PMID>
  </reference>
  <reference>
    <citation>Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-Optimized Cardiac Resynchronization Therapy to Maximize Electrical Resynchronization: A Feasibility Study. Circ Arrhythm Electrophysiol. 2019 Feb;12(2):e006934. doi: 10.1161/CIRCEP.118.006934.</citation>
    <PMID>30681348</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac resynchronization therapy</keyword>
  <keyword>His bundle pacing</keyword>
  <keyword>Haemodynamics</keyword>
  <keyword>ECGI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bundle-Branch Block</mesh_term>
    <mesh_term>Heart Block</mesh_term>
    <mesh_term>Cardiac Conduction System Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share the electrical data obtained from non-invasive electrical mapping with Medtronic (industry company)</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>3 years</ipd_time_frame>
    <ipd_access_criteria>Medtronic will only have access to anonymised data in the form of non-invasive electrical maps (ECGi, CardioInsight)</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

